Comparing Antipsychotic Medications in LBD Over Time

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO · Oct 18, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two medications, pimavanserin and quetiapine, to see which one better helps people with hallucinations or delusions caused by Parkinson's disease or dementia with Lewy bodies (together known as Lewy body disease). The goal is to find out if one medication is more effective than the other when prescribed in a regular doctor's office setting.

To participate in this study, patients must be visiting the neurology clinic at UT Health San Antonio and have been diagnosed with psychosis related to Parkinson's disease or dementia with Lewy bodies. They should also need a new antipsychotic medication. If you or someone you know is interested in joining, it's important to note that participants will need to discuss the study with their healthcare provider, who must feel comfortable prescribing and managing both medications. Throughout the trial, participants will receive care and support as they try one of the two medications to help manage their symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients seen in the neurology clinic at UT Health San Antonio
• • Diagnosed with psychosis due to PD or DLB
• • Requiring initiation of an antipsychotic medication
• • Clinical equipoise between quetiapine and pimavanserin must exist
• • The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin
• Exclusion Criteria:
• • Medical contraindication to either medication
• • Caregiver unavailable to complete NPI-Q
• • Currently taking an antipsychotic medication
• • Prescribing provider unwilling to manage either medication